Drugs / EGF Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02187367 | May 2015 → May 2019 | non-small cell lung carcinoma | Bioven Europe | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGF Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02187367 ↗ |
| Modality | Vaccine | “The vaccine contains humanized recombinant antigen” NCT02187367 ↗ |
| Target | EGF | “antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation” NCT02187367 ↗ |